We are incredibly excited to announce that Gomekli (mirdametinib) has been FDA-approved for the treatment of NF1-related plexiform neurofibromas in both adults and children! Gomekli is a MEK inhibitor developed by SpringWorks Therapeutics for use in adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN).
A plexiform neurofibroma is a type of tumor that develops along multiple nerve pathways. These typically benign tumors can grow over time, often affecting surrounding tissues, muscle, and bone—and, in rare cases, can become cancerous. They are often difficult to remove surgically.
This is the second-ever FDA-approved treatment for NF, and the FIRST approved for adult use.
We are so grateful to those who worked tirelessly to develop this life-changing drug. Each and every hour of research gets us closer to more treatment options for those living with NF—and closer to a cure.
For more information: gomekli.com or springworkstx.com
Read the press release: http://bit.ly/4gCnupg